Tardive Dyskinesia Market Overview
As per MRFR analysis, the Tardive Dyskinesia Market Size was estimated at 1.45 (USD Billion) in 2022.
The Tardive Dyskinesia Market Industry is expected to grow from 1.51(USD Billion) in 2023 to 2.1 (USD Billion) by 2032. The Tardive Dyskinesia Market CAGR (growth rate) is expected to be around 3.76% during the forecast period (2024 - 2032).
Key Tardive Dyskinesia Market Trends Highlighted
The Tardive Dyskinesia market is witnessing advancements in research and development, leading to the emergence of novel therapies and treatment strategies. Key market drivers include the rising prevalence of mental health disorders, increased awareness about tardive dyskinesia, and the need for effective and safe treatment options. Opportunities for exploration lie in the development of personalized treatment plans targeted drug delivery systems, and the integration of technology into patient management. Recent trends have emphasized the importance of early diagnosis and intervention, as well as the role of patient education and support in improving outcomes. With the increasing burden of mental health disorders and the associated impact on individuals and society, the Tardive Dyskinesia market is projected to continue its growth in the coming years.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Tardive Dyskinesia Market Drivers
Growing Prevalence of Mental Health Conditions
A major market industry driver is the increasing pervasiveness of mental health conditions, such as schizophrenia and bipolar disorder. These conditions have contributed to the demand for antipsychotic medications, which mirrors the number of individuals diagnosed with mental health disorders. The continued growth in diagnosis amplifies the potential of developing tardive dyskinesia. As such, the growth in the prevalence of these health conditions has resulted in a surge of demand for an effective tier treatment.This has consequently ignited the growth of the Tardive Dyskinesia Market Industry.
Rising Awareness and Recognition of Tardive Dyskinesia
Increased awareness, as well as improved recognition of tardive dyskinesia among the general population and healthcare workers, are major drivers of the Tardive Dyskinesia Market Industry. Historically, the disorder had been widely misdiagnosed or neglected. However, the understanding of the condition has increased, and its impacts on patients’ quality of life began to be acknowledged. Nowadays, there is a higher level of public demand for diagnostic and treatment services for the disorder, thus promoting the Tardive Dyskinesia Market Industry growth.
Development of Novel Therapies
The development of novel therapies for tardive dyskinesia is also contributing to the growth of the Tardive Dyskinesia Market Industry. In recent years, there have been significant advances in the understanding of the pathophysiology of tardive dyskinesia, which has led to the development of new and more effective treatments. These new therapies are offering hope to individuals with tardive dyskinesia, and they are also driving the growth of the Tardive Dyskinesia Market Industry.
Tardive Dyskinesia Market Segment Insights
Tardive Dyskinesia Market Treatment Type Insights
The Tardive Dyskinesia Market segmentation by Treatment Type comprises Medications, Behavioral Therapies, Deep Brain Stimulation and Vagus Nerve Stimulation. Medications held the dominant share in the market in 2023, and it is projected to maintain its dominance throughout the forecast period. The growth of the segment can be attributed to the widespread use of antipsychotics, which causes tardive dyskinesia as a side effect. However, the Behavioral Therapies segment is expected to register the highest CAGR during the forecast period. Growth of this segment can be attributed to the increasing awareness about the advantages of behavioral therapies in managing symptoms of tardive dyskinesia.Key drugs used for the treatment of the condition include anticholinergics, dopamine agonists, and benzodiazepines. Anticholinergics act by blocking the action of acetylcholine, which is a neurotransmitter that controls the movement of muscles. Dopamine agonists act by stimulating the dopamine receptors present in the brain, which helps improve the control over muscles. However, benzodiazepines act by reducing anxiety and muscle tension. Behavioral Therapies tackle the condition with the help of habit reversal training, cognitive behavioral therapy and supported employment.Habit reversal training is a therapy that helps patients identify and change the behaviors that are linked to the condition. Cognitive behavioral therapy is a type of therapy that helps patients to change thoughts and beliefs that are linked to tardive dyskinesia. Supported employment is a therapy that helps patients find and keep a job, which will improve the quality of life of the patient. Both Deep Brain Stimulation and Vagus Nerve Stimulation are surgical procedures that can be used to treat tardive dyskinesia. DBS involves surgically implanting a device in the brain, which sends electrical impulses to areas of the brain that are linked to movement.VNS involves placing a device in the chest that stimulates the vagus nerve, which is a nerve that connects the brain, stomach and intestines. Both procedures may be effective in reducing symptoms of tardive dyskinesia but are generally used in patients who have not responded to other treatments.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Tardive Dyskinesia Market Severity Insights
The severity of Tardive Dyskinesia can vary widely, ranging from mild to moderate to severe. The Tardive Dyskinesia Market segmentation by severity provides valuable insights into the distribution and impact of the condition. In 2023, the mild severity segment accounted for approximately 45% of the market, indicating a significant prevalence of less severe cases. The moderate severity segment followed with a share of around 35%, while the severe segment accounted for the remaining 20%. This data suggests that a large proportion of Tardive Dyskinesia cases are manageable and treatable, with only a smaller percentage experiencing severe symptoms.Understanding the severity distribution is crucial for developing targeted therapies and interventions to address the specific needs of patients with varying levels of impairment.
Tardive Dyskinesia Market Clinical Presentation Insights
Clinical Presentation Orofacial-lingual dyskinesia is the most common type of TD, affecting approximately 50% of patients. It is characterized by involuntary movements of the mouth, tongue and lips. Limb dyskinesia, which affects the arms and legs, is the second most common type, affecting approximately 30% of patients. The growth of the market is attributed to the increasing prevalence of TD, the rising number of elderly patients, and the growing demand for effective treatments.
Tardive Dyskinesia Market Underlying Causes Insights
The Tardive Dyskinesia Market is segmented into various categories, including underlying causes. Key underlying causes of Tardive Dyskinesia include Antipsychotic Medications, Genetics, and Neurological Disorders. Antipsychotic Medications are widely used to treat psychiatric conditions and are a major contributor to the development of Tardive Dyskinesia. The Tardive Dyskinesia Market revenue attributable to Antipsychotic Medications is estimated to reach 0.95 Billion USD by 2023. Genetics also plays a role in the development of Tardive Dyskinesia, with certain genetic variations increasing the risk of developing the condition.The Tardive Dyskinesia Market segmentation by underlying causes provides valuable insights into the factors driving the market growth and helps in developing targeted strategies for prevention and treatment.
Tardive Dyskinesia Market Regional Insights
The market growth is attributed to the increasing prevalence of mental disorders and the growing geriatric population, leading to a higher incidence of tardive dyskinesia. Regionally, North America held the largest market share in 2023, accounting for approximately 40% of the global market revenue. The high prevalence of mental disorders, coupled with the advanced healthcare infrastructure and the presence of leading pharmaceutical companies in the region, contribute to its dominance. Europe accounted for the second-largest market share, driven by factors such as the increasing aging population and the rising awareness of tardive dyskinesia.The APAC region is anticipated to witness the fastest growth over the forecast period, owing to the rising prevalence of mental disorders, the growing geriatric population, and the increasing healthcare expenditure in developing countries such as China and India. South America and MEA are expected to experience steady growth, supported by the growing awareness of tardive dyskinesia and the increasing availability of treatment options.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Tardive Dyskinesia Market Key Players And Competitive Insights
Key players in the Tardive Dyskinesia Market are continuously involved in gaining a competitive edge in the market by investing in research and development of new and effective drugs. In the Tardive Dyskinesia Market, successful key market players adopt the strategies of partnerships, mergers and acquisitions. In 2021, Teva Pharmaceutical Industries Ltd. acquired Auspex Pharmaceuticals, Inc. The latter is a biopharmaceutical company involved in the development of novel therapies to address unmet medical needs in the treatment of central nervous system disorders. This enabled Teva to expand its major development program in movement disorders, especially including Tardive Dyskinesia. In addition to this, pharmaceutical companies are closely working with research and academic institutions in developing innovative treatment options and expansions in the Tardive Dyskinesia Market. The development in the Tardive Dyskinesia Market is in response to the increasing prevalence of mental health disorders and issues such as addiction, tolerance, dependence, apathy, and disorganized thinking. Other factors, such as increasing awareness regarding Tardive Dyskinesia, healthcare expenditure, and others, are driving the Tardive Dyskinesia Market.Teva Pharmaceutical Industries Ltd. is one of the key players involved in the Tardive Dyskinesia Market. The company is actively involved in the provision and development of innovative and effective treatments for patients around the world suffering from central nervous system disorders. The Tardive Dyskinesia Market player provides a vast number of medications in its product lines for the treatment of Tardive Dyskinesia, which includes tetrabenazine, deutetrabenazine and Amantadine. The major part of the Teva Pharmaceutical Industries Ltd. business is in the United States only. The company is actively engaged in the expansion of its global footprint and is in pursuit of getting maximum benefit from the rising demand for effective Tardive Dyskinesia treatments. The company works in association with the U.S. Federal Trade Commission and the U.S. Department of Justice for successful mergers and acquisitions.
Key Companies in the Tardive Dyskinesia Market Include
- Lundbeck
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- BristolMyers Squibb Company
- Cadila Healthcare Ltd.
- Merck Co., Inc.
- AbbVie Inc.
- GlaxoSmithKline plc
- Eli Lilly and Company
- Intas Pharmaceuticals Ltd.
- AstraZeneca plc
- Pfizer Inc.
- Otsuka Pharmaceutical Co., Ltd.
- Johnson Johnson
Tardive Dyskinesia Market Industry Developments
The Tardive Dyskinesia Market is projected to reach USD 2.1 billion by 2032, exhibiting a CAGR of 3.76% during the forecast period (2024-2032). Rising prevalence of mental disorders, increasing adoption of antipsychotic medications, and growing awareness about tardive dyskinesia are the key factors driving market growth. Additionally, advancements in drug development and the introduction of novel therapies are expected to contribute to market expansion. Key players in the market include Teva Pharmaceutical Industries Ltd., AbbVie Inc., and Lundbeck A/S, among others. Recent news developments include the approval of Ingrezza (valbenazine) by the U.S. Food and Drug Administration (FDA) for the treatment of tardive dyskinesia in adults.
Tardive Dyskinesia Market Segmentation Insights
- Tardive Dyskinesia Market Treatment Type Outlook
- Medications
- Behavioral Therapies
- Deep Brain Stimulation
- Vagus Nerve Stimulation
- Tardive Dyskinesia Market Severity Outlook
- Tardive Dyskinesia Market Clinical Presentation Outlook
- Orofacial-lingual Dyskinesia
- Limb Dyskinesia
- Trunk Dyskinesia
- Tardive Dyskinesia Market Underlying Causes Outlook
- Antipsychotic Medications
- Genetics
- Neurological Disorders
- Tardive Dyskinesia Market Regional Outlook
- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa
| Report Attribute/Metric |
Details |
| Market Size 2022 |
1.45(USD Billion) |
| Market Size 2023 |
1.51(USD Billion) |
| Market Size 2032 |
2.1(USD Billion) |
| Compound Annual Growth Rate (CAGR) |
3.76% (2024 - 2032) |
| Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year |
2023 |
| Market Forecast Period |
2024 - 2032 |
| Historical Data |
2019 - 2023 |
| Market Forecast Units |
USD Billion |
| Key Companies Profiled |
Lundbeck, Novartis AG, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., BristolMyers Squibb Company, Cadila Healthcare Ltd., Merck Co., Inc., AbbVie Inc., GlaxoSmithKline plc, Eli Lilly and Company, Intas Pharmaceuticals Ltd., AstraZeneca plc, Pfizer Inc., Otsuka Pharmaceutical Co., Ltd., Johnson Johnson |
| Segments Covered |
Treatment Type, Severity, Clinical Presentation, Underlying Causes, Regional |
| Key Market Opportunities |
1 Growing prevalence of tardive dyskinesia in the geriatric population2 Increasing awareness of the condition3 Emerging therapies targeting the underlying pathophysiology4 Growing research and development efforts5 Technological advancements in diagnosis and management |
| Key Market Dynamics |
Rising prevalence of mental health disorders Growing geriatric population Increasing adoption of atypical antipsychotics Technological advancements in drug development and Expanding healthcare infrastructure. |
| Countries Covered |
North America, Europe, APAC, South America, MEA |
Frequently Asked Questions (FAQ) :
The Tardive Dyskinesia Market was valued at USD 1.51 billion in 2023 and is projected to reach USD 2.1 billion by 2032, exhibiting a CAGR of 3.76% during the forecast period.
Regionally, the market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
The involuntary movements segment is expected to hold the largest market share, owing to the rising prevalence of neurological disorders and increasing awareness about tardive dyskinesia.
The key competitors in the market include AbbVie, Alkermes, Amneal Pharmaceuticals, Apotex, Cipla, Dr. Reddy's Laboratories, Glenmark Pharmaceuticals, Hikma Pharmaceuticals, Mylan, and Novartis.
Increasing prevalence of neurological disorders, rising awareness about tardive dyskinesia, and the growing geriatric population are the key growth drivers of the market.
Lack of effective treatment options and side effects associated with the available therapies are the key challenges faced by the market.
Recent developments include the approval of new therapies such as valbenazine and deutetrabenazine, and the ongoing research and development of novel treatment approaches.
Technological advancements such as wearable devices and remote monitoring systems are expected to enhance patient care and improve treatment outcomes.
Stringent regulatory requirements and the need for clinical trials add to the challenges in the market.
With the rising demand for effective therapies and the increasing prevalence of neurological disorders, the future growth prospects of the Tardive Dyskinesia Market appear promising.
